07-30 GSK global supply chain director sells 38,000 shares AN
07-30 GSK, Relation Therapeutics to Collaborate on Human Cellular Perturbation Data MT
07-30 GSK : Deutsche Bank gives a Neutral rating ZD
07-30 GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal RE
07-30 Relation Therapeutics Limited and Glaxosmithkline plc Announce Expanded Collaboration to Generate Large-Scale Human Cellular Perturbation Datasets CI
07-30 GSK, Relation Therapeutics Collaborate on Human Cellular Data Project MT
07-30 Goldman Sachs still cautious about GSK Zonebourse
07-29 GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment MT
07-29 GSK : DZ Bank remains Neutral ZD
07-29 GSK : JP Morgan reaffirms its Sell rating ZD
07-29 GSK plc, Q2 2026 Earnings Call, Jul 28, 2026
07-28 GSK plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-28 Gsk plc Declares Second Interim Dividend for the Second Quarter of 2026, Payable on 8 October 2026 CI
07-28 GSK plc: Another beat; we appreciate the new CEO's aggressive intent Alphavalue
07-28 GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint MT
07-28 GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline -- Update DJ
07-28 GSK : JP Morgan gives a Sell rating ZD
07-28 GSK : Bernstein maintains a Buy rating ZD
07-28 GSK : Jefferies remains its Buy rating ZD
07-28 GSK to Build New Global Research Center in Cambridge MT
07-28 GSK Launches Three-year Cost Savings Plan Amid Higher Second-quarter Sales, Lower Profits MT
07-28 GSK plc Announces Plans to Establish a Major New Global R&D Centre in Cambridge, UK CI
07-28 GSK unveils its quarterly results, trial data and a new R&D center Zonebourse
07-28 GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline DJ
07-28 Gsk plc Licensor Hansoh Pharmaceutical Group Announces Positive Results from Second Phase Iii Trial for Ris-Rez in China CI
No results match your criteria